|
WO2009091609A1
|
|
A method for treating rapamycin induced diabetes-like syndrome using trodusquemine
|
|
CA2697744A1
|
|
A method for treating diabetes
|
|
WO2008031113A2
|
|
Improved method for inhibition of neovascularization
|
|
TW200810765A
|
|
Induction of weight loss and the selective inhibition of PTP1B
|
|
AU2007240652A1
|
|
Induction of weight loss and the selective inhibition of PTP1B
|
|
CN101472596A
|
|
Induction of weight loss and the selective inhibition of PTP1B
|
|
WO2006119211A2
|
|
Methods and compositions for treating ocular disorders
|
|
CA2606077A1
|
|
Polymorphic and amorphous salt forms of squalamine dilactate
|
|
EP1633734A2
|
|
Mucin synthesis inhibitors
|
|
US2003236220A1
|
|
Mucin synthesis inhibitors
|
|
CA2455975A1
|
|
Mucin synthesis inhibitors
|
|
EP1499633A2
|
|
Hagfish cathelin-associated antimicrobial peptides and genes
|
|
AU2002300302B2
|
|
Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds
|
|
WO02100432A1
|
|
Methods for the modulation of il-13
|
|
JP2002338494A
|
|
Mucin synthesis inhibitor
|
|
JP2002338493A
|
|
Mucin synthesis inhibitor
|
|
WO0179255A1
|
|
A process for the preparation of 7.alpha.-hydroxy 3-aminosubstituted sterols using intermediates with an unprotected 7.alpha.-hydroxy group
|
|
AU4572601A
|
|
A method for stimulation of defensin production
|
|
US6596712B2
|
|
Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
|
|
AU2001234671B2
|
|
Mucin synthesis inhibitors
|
